Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000379998 | SCV000357780 | uncertain significance | Thrombocythemia 1 | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000266369 | SCV000357781 | uncertain significance | Congenital amegakaryocytic thrombocytopenia | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002520491 | SCV002962203 | uncertain significance | Congenital amegakaryocytic thrombocytopenia; Essential thrombocythemia | 2021-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with glutamic acid at codon 446 of the MPL protein (p.Gly446Glu). The glycine residue is weakly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. This variant is present in population databases (rs561724539, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with MPL-related conditions. ClinVar contains an entry for this variant (Variation ID: 297406). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |